| Liu, Hong |
| Recruiting | 4 | 1428 | RoW | Indomethacin SR, YINDUOMEIXIN, Placebos, sham | Peking Union Medical College Hospital | Acute Pancreatitis, Complication, Mortality Rate, Organ Failure, Multiple | 06/28 | 06/30 | | |
NCT04134026: Evaluate the Efficacy and Safety of HIF-PHI for the Treatment of Anemia and Risks of Cardiovascular and Cerebrovascular Events in ESRD Newly Initiated Dialysis Patients |
|
|
| Not yet recruiting | 4 | 400 | RoW | HIF-PHI, Epoetin Alfa, Epogen | Second Xiangya Hospital of Central South University | Anemia in Incident Dialysis Patients | 10/23 | 10/24 | | |
NCT06142552: Phase 3 Clinical Project of Pegylated Recombinant Human Coagulation Factor VIII-Fc Fusion Protein |
|
|
| Recruiting | 3 | 120 | RoW | FRSW117, Recombinant human coagulation factor Ⅷ-Fc fusion protein for injection | Jiangsu Gensciences lnc. | Severe Hemophilia A | 01/26 | 09/26 | | |
TAPIS, NCT06316570: Ticagrelor With Aspirin Dual Antiplatelet Therapy Combined With Intravenous Thrombolysis for Ischemic Stroke |
|
|
| Recruiting | 3 | 1380 | RoW | Early Dual Antiplatelet Therapy, Ticagrelor and Aspirin, Placebo, Placebo of Ticagrelor and Aspirin | Beijing Tiantan Hospital | Ischemic Stroke, Acute | 12/25 | 12/26 | | |
BENCH, NCT04939142: A Study of Evaluating the Safety and Efficacy of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) |
|
|
| Active, not recruiting | 3 | 150 | RoW | SVd (Selinexor+Bortezomib+dexamethasone), Vd (Bortezomib+dexamethasone) | Antengene Corporation | Relapsed or Refractory Multiple Myeloma | 07/24 | 10/24 | | |
NCT05173272: Induction Chemotherapy Combined With Immunotherapy Followed by Concurrent Chemoradiation in Advanced Cervical Cancer |
|
|
| Recruiting | 3 | 286 | RoW | Neoadjuvant Therapy, Neoadjuvant chemotherapy combined with Serplulimab, CCRT, chemoradiation, Brachytherapy | Sichuan Cancer Hospital and Research Institute | Cervical Cancer | 12/27 | 12/28 | | |
NCT04736186: Prevention and Treatment of Pyrrolitinib-associated Diarrhea |
|
|
| Recruiting | 2/3 | 470 | RoW | Loperamide, Loperamide and golden bifid, Loperamide and montmorillonite powder | Tianjin Medical University Cancer Institute and Hospital | Breast Cancer | 10/22 | 04/23 | | |
NCT04836520: SHR6390 Combined With Anastrozole for Preoperative Treatment of Breast Cancer. |
|
|
| Completed | 2 | 20 | RoW | SHR6390+anatrozole | Tianjin Medical University Cancer Institute and Hospital, Jiangsu HengRui Medicine Co., Ltd. | Breast Cancer | 02/23 | 03/23 | | |
NCT05641506: A Chinese Patent Medicine Yangzhengxiaoji Capsule to Improve the Nausea of Niraparib in the Maintenance Treatment in Ovarian Cancer |
|
|
| Not yet recruiting | 2 | 50 | RoW | Yangzheng Xiaoji, Niraparib | Sichuan Cancer Hospital and Research Institute | Ovarian Cancer | 10/23 | 05/25 | | |
| Recruiting | 2 | 86 | RoW | Penpulimab, Anlotinib | Sichuan Cancer Hospital and Research Institute | Gynecological Cancer | 12/24 | 12/25 | | |
NCT04562870 / 2020-003809-60: A Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Participants with Previously Treated Myelofibrosis |
|
|
| Active, not recruiting | 2 | 112 | Europe, US, RoW | Selinexor, Physician's Choice Treatment | Karyopharm Therapeutics Inc | Myelofibrosis | 01/25 | 01/25 | | |
|
|
| Active, not recruiting | 1/2 | 121 | RoW | CAR-BCMA T Cells | CARsgen Therapeutics Co., Ltd., Beijing Chao Yang Hospital, The First Affiliated Hospital of Soochow University, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Tianjin Medical University General Hospital, First Affiliated Hospital of Zhejiang University, Beijing Hospital, Shanghai Tongji Hospital, Tongji University School of Medicine, First Affiliated Hospital of Wenzhou Medical University, Xiangya Hospital of Central South University, Peking University People's Hospital, Qilu Hospital of Shandong University, Sun Yat-sen University, First Affiliated Hospital, Sun Yat-Sen University | Multiple Myeloma | 12/24 | 12/25 | | |
| Recruiting | 1/2 | 430 | RoW | IBI363, IBI325, Lenvatinib | Hunan Province Tumor Hospital, Xiangya Hospital of Central South University | Advanced Solid Tumor | 12/26 | 09/28 | | |
NCT06756321: A Study of CAR T-Cells in Relapsed/Refractory Hematologic Malignancy |
|
|
| Recruiting | 1 | 9 | RoW | anti-CD19-CAR T-cells, or anti-CD30-CAR T-cells, or anti-CD20/CD30-CAR T-cells, Fludarabine, Cyclophosphamide | Affiliated Hospital of Nantong University, Shanghai First Song Biotechnology Co., LTD | Relapsed/refractory Lymphoma, Relapsed/Refractory Leukemia | 03/25 | 03/26 | | |
NCT04993794: Additive Anti-inflammatory Action for Critically Ill Patients With Cardiovascular Surgery (Xuebijing) IV |
|
|
| Recruiting | N/A | 200 | RoW | XueBiJing Injection, Normal saline | Nanjing Medical University | Cardiovascular Disease, Aortic Dissection, Coronary Artery Disease, Valve Heart Disease, Congenital Heart Disease, Critical Illness | 12/22 | 12/22 | | |
PANDA V, NCT04444349: Protective Effect of CoQ10 Against Negative Inflammatory Response and Organ Dysfunction in Cardiovascular Surgery |
|
|
| Recruiting | N/A | 500 | RoW | Coenzyme Q10, ubiquinone, Standard Medical Therapy | Nanjing Medical University, The First Affiliated Hospital with Nanjing Medical University, Beijing Anzhen Hospital, West China Hospital, The First Affiliated Hospital of Guangzhou Medical University | Cardiovascular Disease | 12/25 | 12/25 | | |
NTU-CML-001, NCT05152537: FLOR3 Gene Polymorphism in Predicting Outcomes of Tyrosine Kinase Inhibitor（TKI）Stopping in Chronic Myeloid Leukemia |
|
|
| Recruiting | N/A | 15 | RoW | | Affiliated Hospital of Nantong University | Folate, CML, Treatment-free Remission | 06/23 | 12/23 | | |
NCT04216823: Perfusion Index as an Objective Measure for Supraclavicular Brachial Plexus Block in Pediatric Patients |
|
|
| Completed | N/A | 104 | RoW | perfusion index | Tongji Hospital | Supraclavicular Brachial Plexus Block | 06/23 | 06/23 | | |
NCT05686863: Remiazolam Combined With Esketamine in Painless Bidirectional Endoscopy in Children |
|
|
| Completed | N/A | 106 | RoW | Remimazolam, Rema, Esketamine, Esket, Propofol, Prop, remifentanil, remifen | Tongji Hospital | Drug Effect | 07/23 | 07/23 | | |
PANDA, NCT04699279: Protective Effect of Statin Against Negative Cardiovascular Remodeling and Organ Dysfunction After Acute Aortic Syndrome Surgery ( III) |
|
|
| Recruiting | N/A | 300 | RoW | Rosuvastatin 10mg | Nanjing Medical University, Beijing Anzhen Hospital, West China Hospital, The First Affiliated Hospital of Guangzhou Medical University, The Affiliated Hospital of Qingdao University Medical College | Acute Aortic Syndrome, Aortopathy | 12/24 | 12/24 | | |
NCT05487469: Thymosin α1 Use in Rheumatic Heart Disease Patients Undergoing Cardiac Surgery on Cardiopulmonary Bypass |
|
|
| Recruiting | N/A | 200 | RoW | Thymosin Alpha1, Blank Control | Nanjing Medical University | Rheumatic Heart Disease, Cardiopulmonary Bypass, Immunotherapy | 12/23 | 12/23 | | |
Panda II, NCT05339529: Protective Effect of Thymosin Α1 Against Negative Immune Dysregulation and Organ Dysfunction After Acute Aortic Dissection Surgery (PANDA II) |
|
|
| Recruiting | N/A | 330 | RoW | Thymosin Alpha1, 28A-Glycine-28B-L-Arginine-28C-L-Glutamic Acid-28D-L-Alanine-28E-L-Proline-28F-L-Alanine-28G-L-Asparagine-, Blank control | Nanjing Medical University, Beijing Anzhen Hospital, Second Affiliated Hospital of Nanchang University, Qilu Hospital of Shandong University, The First Affiliated Hospital of Guangzhou Medical University, Northern Jiangsu People's Hospital, Guangdong Provincial People's Hospital, First Affiliated Hospital of Kunming Medical University, Nanjing First Hospital, Nanjing Medical University, Shanghai East Hospital,Tongji University School of Medicine, The Seventh Affiliated Hospital of Xinjiang Medical University, Teda International Cardiovascular Hospital, Tianjin, China, First Affiliated Hospital Bengbu Medical College, West China Hospital Affiliated with Sichuan University | Acute Aortic Syndrome, Aortic Dissection Type a | 12/25 | 12/25 | | |
NCT05782881: High Risk Population of Cardiovascular Disease in Hubei Province Screening and Intervention Program |
|
|
| Recruiting | N/A | 16000 | RoW | phone calls and encouraging patients' lifestyle change and medication adherence, Statin, Angiotensin-converting enzyme inhibitor, Angiotensin receptor neprilysin inhibitor, Glucagon-like peptide-1, Sodium-dependent glucose transporters 2 | Wuhan Union Hospital, China, Peking University First Hospital | Cardiovascular Diseases, Diabetes Mellitus, Type 2, Coronary Disease | 12/23 | 12/24 | | |
NCT05881655: Slow Myopia Progression With Different Irradiance Light |
|
|
| Recruiting | N/A | 75 | RoW | Airdoc Red Lighting Device, Repeated Red Light, Low Lever Laser Therapy, Low Intensity Light Therapy, Photobiomodulation Therapy, Seconee, 650nm Red Light, Special Spectacles to Control Myopia, Essilor® Stellest™ Lenses, H.A.L.T lens | Beijing Airdoc Technology Co., Ltd., Shanghai Children's Medical Center | Myopia, Progressive | 05/24 | 12/25 | | |
PANDA VI, NCT06195267: Protective Effect of Sivelestat Against Negative Pulmonary Function and Organ Dysfunction After Cardiovascular Surgery |
|
|
| Recruiting | N/A | 500 | RoW | Sivelestat, Blank control | Nanjing Medical University, The First Affiliated Hospital with Nanjing Medical University, Beijing Anzhen Hospital | Aortic Dissection, Systemic Inflammatory Response Syndrome, Cardiovascular Diseases (CVD) | 12/25 | 12/25 | | |
COSEFDIP, NCT05755659: Clinical on the Safety and Efficacy of Fosaprepitant Dimeglumine for Injection in the Prevention of CINV. |
|
|
| Recruiting | N/A | 3000 | RoW | Fosaprepitant Dimeglumine for Injection, ShanQi®️ | Xijing Hospital | Neoplasms | 10/24 | 12/24 | | |
PANDA, NCT06707350: Protective Effect of RIPC Against Negative Inflammatory Response and Organ Dysfunction After Cardiovascular Surgery (Panda VII) |
|
|
| Not yet recruiting | N/A | 500 | RoW | Remote ischemic preconditioning (RIPC), sham condition (control group) | Nanjing Medical University, The First Affiliated Hospital with Nanjing Medical University | Cardiopulmonary Bypass, Cardiovascular Diseases, Inflammatory Response During Cardiac Surgery | 12/25 | 12/25 | | |
NCT04837222: A Study of Brentuximab Vedotin in Adults With CD30-positive Lymphoma |
|
|
| Active, not recruiting | N/A | 1000 | RoW | No Intervention | Takeda | Lymphoma | 06/26 | 06/26 | | |
NCT06723366: Protective Effect of Angong Niuhuang Against Negative Inflammatory Response and Neurologic Dysfunction After Cardiovascular Surgery |
|
|
| Not yet recruiting | N/A | 120 | RoW | Angong Niuhuang Pill (ANP), Control (Standard treatment) | Nanjing Medical University, The First Affiliated Hospital with Nanjing Medical University, Beijing Anzhen Hospital, Capital Medicine University | Cardio-pulmonary Bypass, Cardiovascular Surgery, Cerebral Protection, Brain Injury | 12/25 | 12/25 | | |
PANDA, NCT06730802: Protective Effect of PCSK9 Inhibitor Against Negative Inflammatory Response and Organ Dysfunction After Coronary Artery Bypass Grafting ( VIII) |
|
|
| Not yet recruiting | N/A | 400 | RoW | PCSK9 inhibitor, Statin | Nanjing Medical University, The First Affiliated Hospital with Nanjing Medical University, Beijing Anzhen Hospital | Myocardial Ischaemic Syndrome, Coronary Heart Disease | 12/26 | 12/26 | | |
NCT01932411: Factors Affect Outcomes in Cardiovascular Surgery |
|
|
| Recruiting | N/A | 5000 | US | | University of California, Davis | Coronary Artery Disease, Valvular Diseases, Vascular Diseases | 02/25 | 07/25 | | |
| Recruiting | N/A | 2000 | RoW | Renal replacement therapy | Nanjing Medical University | Acute Kidney Injury, Cardiac Surgery | 12/25 | 12/25 | | |
NCT04398992: Additive Anti-inflammatory Action for Aortopathy & Arteriopathy |
|
|
| Enrolling by invitation | N/A | 10000 | RoW | observation | Nanjing Medical University, Beijing Anzhen Hospital | Acute Aortic Syndrome | 12/40 | 12/40 | | |
| Recruiting | N/A | 500 | RoW | soluble ST2 | Nanjing Medical University | Cardiovascular Disease | 12/25 | 12/25 | | |
PANDA IV, NCT04444362: Protective Effect of Probacine Against Negative Gut Metabolism and Organ Dysfunction After Cardiovascular Surgery |
|
|
| Enrolling by invitation | N/A | 500 | RoW | Intestinal Microbiota Transplant (IMT) Capsules | Nanjing Medical University, Beijing Anzhen Hospital, Shanghai East Hospital of Tongji University, West China Hospital, The First Affiliated Hospital of Guangzhou Medical University | Cardiovascular Disease, Cardiopulmonary Bypass | 12/25 | 12/25 | | |
PANDA, NCT06728605: Protective Effect of EECP Against Negative Inflammatory Response and Organ Dysfunction After Cardiovascular Surgery |
|
|
| Not yet recruiting | N/A | 400 | RoW | Enhanced External Counterpulsation (EECP), Sham Comparator | Nanjing Medical University, The First Affiliated Hospital with Nanjing Medical University | Coronary Heart Disease (CHD), Cardio-pulmonary Bypass, Congestive Heart Failure Chronic, Cardiogenic Shock Acute | 12/25 | 12/25 | | |
BEST-BAO, NCT05631847: Direct Endovascular Treatment Versus Bridging Treatment In Basilar Artery Occlusive Stroke |
|
|
| Recruiting | N/A | 336 | RoW | Endovascular treatment, Intravenous thrombolysis (Alteplase) | Sichuan Academy of Medical Sciences, Sichuan Provincial People's Hospital | Acute Ischemic Stroke, Basilar Artery Occlusion, Thrombosis, Alteplase, Endovascular Treatment | 01/27 | 05/27 | | |
| Recruiting | N/A | 10000 | RoW | NIS | Second Affiliated Hospital, School of Medicine, Zhejiang University | Psoriasis | 07/30 | 07/30 | | |
NCT05454397: A Study on the Status of Nutritional Risk Screening and Nutritional Therapy in Neurology Hospitalized Stroke Patients |
|
|
| Recruiting | N/A | 2000 | RoW | Observational study, no intervention | Nanfang Hospital of Southern Medical University, First Affiliated Hospital of Fujian Medical University, Yantai Yuhuangding Hospital, The First Hospital of Jilin University, Qilu Hospital of Shandong University, ZHEJIANG PROVINCE XIAOSHAN HOSPITAL, The First People's Hospital of Wenling, Ganzhou People's Hospital, Affiliated Hospital of Jining Medical hospital, Henan Provincial People's Hospital, Zhongda Hospital Southeast University, The Second Affiliated Hospital of Harbin Medical University, The First people's Hospital of Kunshan, The 2nd Affiliated Hospital of Wenzhou Medical University, THE FIRST PEOPLE'S HOSPITAL OF JIASHAN, The First Affiliated Hospital of Xi'an Jiaotong University Medical College, Fujian Province Zhangzhou Hospital, People's Hospital of Chongqing, Nanjing Zijin Hospital, Hangzhou Red Cross Hospital, Wenzhou Hospital of Chinese Medicine, Kaifeng Central Hospital, First Affiliated Hospital of Guangxi Medical University, Zhongshan Hospital of Xiamen University, Xi'an Encephalopathy of Traditional Chinese Medicine Hospital, 903 Hospital of the Chinese People's Liberation Army Joint Logistics and Security Forces, Xiangya Hospital of Central South University, Second Affiliated Hospital of Suzhou University, Tongji Hospital, The Affiliated Hospital o fQingdao University, The First Affiliated Hospital of Anhui Medical University, Yancheng Third People's Hospital, Linyi People's Hospital, Dongfang Hospital of Beijing University of Chinese Medicine, Affiliated Hospital of Qingdao University | Acute Stroke | 10/22 | 10/23 | | |
NCT04970264: A Multicenter, Open and Observational Real World Study on the Prognosis and Treatment in Young Women With Breast Cancer |
|
|
| Recruiting | N/A | 2000 | RoW | | Tianjin Medical University Cancer Institute and Hospital | Breast Cancer | 03/23 | 03/25 | | |
| Recruiting | N/A | 300 | RoW | ECMO | Nanjing Medical University | Cardiogenic Shock, Cardiac Arrest, Heart Failure, Acute Respiratory Failure, Acute Respiratory Distress Syndrome | 12/25 | 12/25 | | |
| Recruiting | N/A | 1000 | RoW | Intra Aortic Balloon Pump | Nanjing Medical University | Acute Coronary Syndrome, Cardiogenic Shock, Coronary Artery Disease, Heart Failure, Left Ventricular Dysfunction, Low Cardiac Output Syndrome, Post-cardiac Surgery | 12/25 | 12/25 | | |
| Zhang, Jian |
HEARTRIP, NCT03809273: Effects of Yangxinshi Pills on the Exercise Tolerance Compared With Trimetazidine in Patients After PCI |
|
|
| Recruiting | 4 | 668 | RoW | Yangxinshi, Trimetazidine, Yangxinshi mimic, Trimetazidine mimic | Shenyang Northern Hospital | Percutaneous Coronary Intervention | 12/20 | 12/20 | | |
NCT04446819: Compression Gloves to Reduce Albumin-binding Paclitaxel Induced Peripheral Sensory and Motor Neurotoxicity (REMAINING) |
|
|
| Recruiting | 3 | 70 | RoW | Compression gloves | Fudan University | Peripheral Neuropathy | 01/22 | 06/22 | | |
NCT03388593: Survival Study of the Recombinant Human Neuregulin-1β in Subjects With Chronic Heart Failure. |
|
|
| Recruiting | 3 | 1600 | RoW | rhNRG-1, Neucardin™, Placebo | Zensun Sci. & Tech. Co., Ltd. | Chronic Heart Failure | 02/26 | 02/26 | | |
TQB2450-III-09, NCT04964479: A Clinical Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsules Versus K Drug in the Treatment of First-line Non-small Cell Lung Cancer(NSCLC) |
|
|
| Recruiting | 3 | 375 | RoW | TQB2450 injection, Anlotinib Hydrochloride Capsules, Pembrolizumab injection, Placebo | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Non Small Cell Lung Cancer | 12/22 | 03/23 | | |
NCT06143553: Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection in the Treatment of Metastatic Breast Cancer |
|
|
| Recruiting | 3 | 168 | RoW | Paclitaxel Polymeric Micelles for Injection, Eribulin Mesilate injection, Capecitabine Tablets, Gemcitabine Hydrochloride for Injection, Vinorelbine Tartrate Injection, Paclitaxel (albumin-bound) | Shanghai Yizhong Pharmaceutical Co., Ltd. | Metastatic Breast Cancer (MBC) | 12/25 | 12/25 | | |
NCT05346861: Pyrotinib Rechallenge in Her2-positive Metastatic Breast Cancer Pretreated With Pyrotinib and Trastuzumab |
|
|
| Recruiting | 3 | 240 | RoW | Trastuzumab plus chemotherapy, Trastuzumab in combination with pyrotinib plus chemotherapy | Fudan University | HER2-positive Breast Cancer, Metastatic Breast Cancer | 10/23 | 10/24 | | |
NCT05949801: Evaluation of the Effect of Injectable Neucardin on Cardiac Function and Reversal Ventricular Remodeling in Patients With Chronic Systolic Heart Failure |
|
|
| Completed | 3 | 202 | RoW | Neucardin, Recombinant human Neuregulin-1 for Injection, Placebo, Excipients of recombinant human neuregulin-1 freeze dried for injection | Zensun Sci. & Tech. Co., Ltd. | Chronic Systolic Heart Failure | 08/24 | 10/24 | | |
| Recruiting | 3 | 224 | RoW | DB-1303/BNT323, T-DM1 | DualityBio Inc., BioNTech SE | HER2-positive Breast Cancer | 02/26 | 02/26 | | |
NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) |
|
|
| Recruiting | 3 | 12500 | Europe, Canada, Japan, US, RoW | Lepodisiran Sodium, LY3819469, Placebo | Eli Lilly and Company | Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a) | 03/29 | 03/29 | | |
GenSci093-301, NCT06449027: Safety, Efficacy and Pharmacokinetic Behavior of Leuprolide Injectable Emulsion for Premenopausal Breast Cancer Subjects. |
|
|
| Not yet recruiting | 3 | 200 | RoW | T Leuprolide Injectable Emulsion, Tamoxifen Citrate Tablets, Leuprorelin Acetate Microspheres for Injection | Changchun GeneScience Pharmaceutical Co., Ltd. | Breast Cancer Subjects | 11/25 | 03/26 | | |
NCT06419621: PM8002 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/Metastatic Triple-negative Breast Cancer |
|
|
| Recruiting | 3 | 360 | RoW | PM8002, Nab-Paclitaxel, Placebo | Biotheus Inc. | Triple Negative Breast Cancer(TNBC) | 07/27 | 07/28 | | |
NCT06382142: A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer |
|
|
| Recruiting | 3 | 406 | RoW | BL-B01D1, Eribulin, Vinorelbine, Gemcitabine, Capecitabine | Sichuan Baili Pharmaceutical Co., Ltd., Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. | Triple-Negative Breast Cancer | 06/26 | 06/26 | | |
NCT06519370: FDA018-ADC Vs Investigator's Choice Chemotherapy to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer |
|
|
| Recruiting | 3 | 350 | RoW | FDA018-ADC, FDA018-Antibody-drug Conjugate, Eribulin, Halaven, Capecitabine, Xeloda, Gemcitabine, Gemzar, Vinorelbine, Navelbine | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. | Triple Negative Breast Cancer | 08/26 | 06/27 | | |
NCT06680921: A Study of SIM0270 Combined with Everolimus Vs. Treatment of Physician's Choice in Patients with ER+/HER2- Advanced Breast Cancer (SIMRISE) |
|
|
| Recruiting | 3 | 460 | RoW | SIM0270, Everolimus (Afinitor®), Exemestane tablets, Fulvestrant injection | Jiangsu Simcere Pharmaceutical Co., Ltd., Nanjing Zaiming Pharmaceutical Co., Ltd. | Locally Advanced or Metastatic Breast Cancer | 08/28 | 08/28 | | |
JSKN003-302, NCT06079983: JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects |
|
|
| Not yet recruiting | 3 | 400 | RoW | JSKN003, Capecitabine tablets, Gemcitabine hydrochloride for injection, Vinorelbine tartrate injection, Paclitaxel for injection (albumin-bound type), Docetaxel injection, Eribulin mesylate injection | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Breast Cancer | 04/25 | 03/29 | | |
| Active, not recruiting | 3 | 600 | Europe, Canada, US, RoW | Gotistobart, A humanized anti-CTLA4 IgG1 monoclonal antibody, ONC-392, BNT316, Docetaxel, Docefrez, Taxotere | OncoC4, Inc., BioNTech SE | Non Small Cell Lung Cancer | 06/26 | 06/27 | | |
| Not yet recruiting | 2/3 | 1800 | RoW | Blinatumomab (Group A), high-dose methotrexate, Venetoclax (nonRand Group), cyclophosphamide, vincristine, dexamethasone, Blinatumomab (Group B) | Institute of Hematology & Blood Diseases Hospital, China | Acute Lymphoblastic Leukemia ALL, Childhood Leukemia, Acute Lymphoblastic, B Cell Acute Lymphoblastic Leukemia (B-ALL) | 12/29 | 06/31 | | |
NCT04303988: A Phase II Study of Triple-negative Breast Cancer Brain Metastases. |
|
|
| Recruiting | 2 | 35 | RoW | SHR-1316, HTI-1088, Bevacizumab, Avastin, Cisplatin/Carboplatin, Bobei | Fudan University | Breast Cancer | 12/24 | 05/25 | | |
NCT05354076: Study on the Correlation Between Immunoglobulin and Liposomal Doxorubicin in Vivo |
|
|
| Recruiting | 2 | 30 | RoW | doxorubicin hydrochloride liposome injection | Fudan University | Advanced Malignant Tumors | 06/22 | 11/22 | | |
NCT04192903: Chidamide Combined With Cisplatin for Relapsed or Metastatic Triple-negative Breast Cancer |
|
|
| Recruiting | 2 | 55 | RoW | Chidamide combined with Cisplatin | Fudan University | Triple-negative Breast Cancer | 06/22 | 06/22 | | |
TEMPLATE, NCT04913571: Tislelizumab in Combination With Eribulin for Patients With Metastatic Previously heaviLy-treAted TriplE-negative Breast Cancer：A Prospective Multiple-center Phase II Study |
|
|
| Not yet recruiting | 2 | 265 | RoW | Eribulin, Tislelizumab | Fudan University | Triple Negative Breast Cancer | 06/22 | 06/23 | | |
NCT04517292: Eribulin Plus Cisplatin Versus Gemcitabine Plus Cisplatin in Triple Negative Breast Cancer (TNBC) |
|
|
| Not yet recruiting | 2 | 160 | RoW | Eribulin,cisplatin, Gemcitabine,cisplatin | Fudan University | Breast Cancer | 07/22 | 10/22 | | |
| Completed | 2 | 37 | RoW | HX008，Niraparib, HX008，Niraparib，Trastuzumab, HX008，Niraparib，Pyrrolitinib | Fudan University | Treatment Efficacy | 08/22 | 02/23 | | |
NCT04780347: Albumin-bound Paclitaxel Combination With Capecitabine Versus Capecitabine Monotherapy in Paclitaxel/Docetaxel-resistant Advanced Breast Cancer |
|
|
| Recruiting | 2 | 92 | RoW | Albumin-bound paclitaxel plus capecitabine, capecitabine | Fudan University | Breast Cancer | 12/22 | 02/23 | | |
NCT04745975: Guided Treatment Based on Mini-PDX in Metastatic Triple Negative Breast Cancer |
|
|
| Recruiting | 2 | 100 | RoW | Personalized treatment guided by mini-PDX and RNA sequencing, Nab paclitaxel, Eribulin, Vinorelbine, Gemcitabine, Capecitabine | Fudan University | Triple Negative Breast Cancer | 01/23 | 01/23 | | |
NCT04778982: Study of KN026 in Combination With Palbociclib and Fulvestrant in Patients With Advanced Breast Cancer |
|
|
| Terminated | 2 | 4 | RoW | KN026 combined with Palbociclib and Fulvestrant, combination | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | HER2-positive Metastatic Breast Cancer | 03/23 | 03/23 | | |
NCT05145907: Study to Evaluate Safety and Efficacy of TJ107 Combine With PD-1 in Patients With Solid Tumors |
|
|
| Active, not recruiting | 2 | 133 | RoW | TJ107 +Pembrolizumab | TJ Biopharma Co., Ltd. | Triple-negative Breast Cancer, Head and Neck Squamous Cell Carcinoma | 06/24 | 12/24 | | |
NCT06332300: An Exploratory Clinical Study of Adebelimumab in Combination With Famitinib and Chemotherapy in Patients With NSCLC |
|
|
| Withdrawn | 2 | 28 | RoW | Adebelimumab+Famitinib + FOLFIRI+Ariely | Jiangsu Province Nanjing Brain Hospital | NSCLC | 02/25 | 02/26 | | |
NCT06413615: A Study of FDA022-BB05 in Advanced/Metastatic Solid Tumors |
|
|
| Recruiting | 2 | 150 | RoW | FDA022-BB05 | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. | Advanced Solid Tumor | 07/25 | 06/26 | | |
NCT06492005: A Clinical Study of 9MW2821 (and PD-1 Inhibitor) in Locally Advanced or Metastatic Triple-Negative Breast Cancer |
|
|
| Recruiting | 2 | 160 | RoW | 9MW2821, PD-1 inhibitior | Mabwell (Shanghai) Bioscience Co., Ltd. | Triple-Negative Breast Cancer | 07/26 | 07/27 | | |
NCT06471205: A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Unresectable Locally Advanced or Recurrent Metastatic Triple-negative Breast Cancer |
|
|
| Recruiting | 2 | 52 | RoW | BL-B01D1, PD-1 Monoclonal Antibody | Sichuan Baili Pharmaceutical Co., Ltd., Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. | Triple-negative Breast Cancer | 07/26 | 07/26 | | |
| Recruiting | 2 | 200 | RoW | Camrelizumab, PD-1 antibody, Gemcitabine, Gem, Induction Cisplatin, DDP, intensity-modulated radiotherapy, IMRT, Concurrent cisplatin | Wei Jiang, Wuzhou Red Cross Hospital, Guangxi Nanxishan Hospital, Laibin People's Hospital, Lingshan people's Hospital | Nasopharyngeal Carcinoma | 04/25 | 04/26 | | |
NCT06042894: A Study of SI-B003 or BL-B01D1+SI-B003 in Patients With Unresectable Locally Advanced or Recurrent Metastatic HER2 Negative Breast Cancer |
|
|
| Recruiting | 2 | 58 | RoW | BL-B01D1, SI-B003 | Sichuan Baili Pharmaceutical Co., Ltd. | Breast Cancer | 12/25 | 12/25 | | |
NCT05253053: To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1/2 | 114 | RoW | TT-00420, Combination Product: Atezolizumab, Combination Product: Nab-Paclitaxel | TransThera Sciences (Nanjing), Inc. | Advanced Solid Tumor, Cholangiocarcinoma, Biliary Tract Cancer, HER2-negative Breast Cancer, Triple Negative Breast Cancer, Small-cell Lung Cancer, Bladder Cancer, Prostate Cancer, Thyroid Cancer, Gastric Cancer, Gallbladder Cancer | 09/24 | 12/24 | | |
| Recruiting | 1/2 | 380 | RoW | PM8002 | Biotheus Inc. | Malignant Neoplasm | 11/25 | 11/25 | | |
NCT05785728: A Study of DB-1202 Monotherapy in Advanced Solid Tumors |
|
|
| Not yet recruiting | 1/2 | 150 | RoW | DB-1202 | DualityBio Inc. | Advanced Solid Tumor | 02/24 | 02/24 | | |
NCT04282031: A Study of BPI-1178 in Patients With Advanced Solid Tumor and HR+/HER2- Breast Cancer |
|
|
| Recruiting | 1/2 | 224 | RoW | BPI-1178, Fulvestrant, Letrozole | Beta Pharma (Suzhou) Co., Ltd. | Advanced Solid Tumor, HR+/HER2- Breast Cancer | 12/24 | 06/25 | | |
| Recruiting | 1/2 | 181 | US, RoW | MRG004A | Shanghai Miracogen Inc. | Advanced or Metastatic Solid Tumors | 04/24 | 06/25 | | |
NCT05048160: A Clinical Study of 6MW3211 Injection in the Treatment of Advanced Malignant Neoplasm |
|
|
| Recruiting | 1/2 | 272 | RoW | Intravenous Infusion | Mabwell (Shanghai) Bioscience Co., Ltd. | Advanced Malignant Neoplasm | 06/24 | 12/24 | | |
CT041-ST-01, NCT04581473: Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection |
|
|
| Recruiting | 1/2 | 192 | RoW | CT041 autologous CAR T-cell injection, CAR T-cell injection, Physician's Choice（Paclitaxel or Irinotecan or Apatinib or Anti-PD-1 antibody）, Best support care(BSC) | CARsgen Therapeutics Co., Ltd., Peking University Cancer Hospital & Institute, Fudan University | Gastric Adenocarcinoma, Pancreatic Cancer, Gastroesophageal Junction Adenocarcinoma | 06/24 | 06/38 | | |
NCT04322006: A Phase I/II Study of TJ004309 for Advanced Solid Tumor |
|
|
| Active, not recruiting | 1/2 | 376 | RoW | TJ004309, Toripalimab | TJ Biopharma Co., Ltd. | Advanced Solid Tumor | 12/24 | 12/24 | | |
NCT05927779: Study of TFX06 in Women With Advanced Breast Cancer. |
|
|
| Recruiting | 1/2 | 74 | RoW | TFX06 tablet | Shenzhen Yangli Pharmaceutical Technology Co., Ltd | ER+, HER2- Advanced Breast Cancer, Metastatic Breast Cancer | 12/24 | 04/25 | | |
| Recruiting | 1/2 | 725 | RoW | JSKN003 | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Advanced Solid Tumor | 12/24 | 12/26 | | |
|
| Recruiting | 1/2 | 404 | US, RoW | Rina-S, PRO1184, Rinatabart sesutecan, GEN1184, Carboplatin, Bevacizumab, Pembrolizumab | Genmab | Platinum-Resistant Ovarian Cancer, Platinum Sensitive Ovarian Cancer (PSOC), High Grade Epithelial Ovarian Cancer, High Grade Serous Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer, Endometrial Cancer, Non-small Cell Lung Cancer, Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer (NSCLC), Mesothelioma, Breast Adenocarcinoma, Triple Negative Breast Cancer, Hormone Receptor-positive/Her2 Negative Breast Cancer | 04/26 | 10/26 | | |
NCT05301764: A Study of LVGN6051 Combined with Anlotinib in Patient with Soft Tissue Sarcoma |
|
|
| Recruiting | 1/2 | 65 | RoW | LVGN6051 and Anlotinib | Lyvgen Biopharma Holdings Limited | Soft Tissue Sarcoma | 03/25 | 10/25 | | |
NCT05803018: A Study of BL-B01D1 in Patients With Multiple Solid Tumors, Including Recurrent or Metastatic Gynecological Malignancies |
|
|
| Recruiting | 1/2 | 32 | RoW | BL-B01D1 | Sichuan Baili Pharmaceutical Co., Ltd., Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. | Gynecological Malignant Tumor, Solid Tumor | 06/25 | 06/25 | | |
NCT05842785: TSN222 in Subjects With Advanced Solid Tumors or Lymphomas |
|
|
| Recruiting | 1/2 | 162 | RoW | Phase I dose escalation, Phase II-HNSCC, Phase II-Advanced melanoma, Phase II-solid tumors or lymphomas | Tyligand Bioscience (Shanghai) Limited | Has a Pathologically Documented Unresectable Locally Advanced or Metastatic Solid Tumor or Lymphoma | 06/25 | 06/26 | | |
NCT05438329: First-in-human Study of DB-1305/BNT325 for Advanced/Metastatic Solid Tumors |
|
|
| Recruiting | 1/2 | 902 | US, RoW | DB-1305/BNT325, DB-1305/BNT325 for Injection, Pembrolizumab, BNT327 | DualityBio Inc., BioNTech SE | Advanced Solid Tumor | 06/25 | 06/25 | | |
| Recruiting | 1/2 | 208 | RoW | 9MW2821 | Mabwell (Shanghai) Bioscience Co., Ltd. | Solid Tumors | 12/25 | 12/25 | | |
NCT05416749: A Clinical Study of 8MW2311 in Subjects With Locally Advanced or Metastatic Solid Tumors |
|
|
| Recruiting | 1/2 | 216 | RoW | 8MW2311 | Mabwell (Shanghai) Bioscience Co., Ltd. | Solid Tumors | 03/26 | 03/26 | | |
NCT05463432: A Study of HR19024 in Subjects With Advanced Solid Tumor |
|
|
| Recruiting | 1a | 180 | RoW | HR19024 | Shanghai Hengrui Pharmaceutical Co., Ltd. | Advanced Solid Tumor | 07/23 | 07/23 | | |
| Completed | 1 | 23 | RoW | Humanized Anti-HER2 Monoclonal Antibody Compound for Injection .R&D code: B002., Biological Products, Humanized Anti-HER2 Monoclonal Antibody Compound for Injection | Shanghai Pharmaceuticals Holding Co., Ltd | Recurrent Breast Cancer, Metastatic Breast Cancer | 04/22 | 04/22 | | |
| Recruiting | 1 | 150 | RoW | GQ1005 | GeneQuantum Healthcare (Suzhou) Co., Ltd. | HER2 Expressing or Mutated Advanced Malignant Solid Tumors | 12/24 | 07/25 | | |
NCT06299124: A Phase I Study of RGT-419B in Patients With HR-Positive, HER2-Negative Advanced Breast Cancer or Other Solid Tumors |
|
|
| Recruiting | 1 | 40 | RoW | RGT-419B, Active drug | Regor Pharmaceuticals Inc. | Breast Cancer, Advanced Solid Tumor | 12/24 | 06/25 | | |
NCT04631835: Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer |
|
|
| Recruiting | 1 | 54 | RoW | HS-10352 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Breast Cancer | 04/23 | 08/23 | | |
NCT05221385: Gentulizumab in Patients With Advanced Solid Malignancies and Non-Hodgkin Lymphoma |
|
|
| Terminated | 1 | 58 | RoW | Gentulizumab | Changchun GeneScience Pharmaceutical Co., Ltd. | Solid Tumor, Non-Hodgkin Lymphoma | 05/23 | 10/23 | | |
NCT06182735: CD70-targeted CAR-NKT Cells(CGC729) Therapy in the Renal Cell Carcinoma |
|
|
| Recruiting | 1 | 9 | RoW | Cyclophosphamide + Fludarabine + Infusion of CAR-NKT Cells | Fudan University | Renal Cell Carcinoma | 01/25 | 01/25 | | |
NCT05078593: A Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of HLX26 Monoclonal Antibody Injection in Patients With Solid Tumor or Lymphoma |
|
|
| Completed | 1 | 18 | RoW | HLX26, Anti-LAG-3 Monoclonal Antibody | Shanghai Henlius Biotech | Solid Tumor, Adult, Lymphoma | 08/23 | 08/23 | | |
